WO2020187298A1 - 鹅去氧胆酸衍生物的制备方法 - Google Patents
鹅去氧胆酸衍生物的制备方法 Download PDFInfo
- Publication number
- WO2020187298A1 WO2020187298A1 PCT/CN2020/080244 CN2020080244W WO2020187298A1 WO 2020187298 A1 WO2020187298 A1 WO 2020187298A1 CN 2020080244 W CN2020080244 W CN 2020080244W WO 2020187298 A1 WO2020187298 A1 WO 2020187298A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- methanol
- acid
- Prior art date
Links
- 0 C[C@](CCC(N(*)*)=O)[C@@](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@](C3)O)[C@@]3C3)C1C2C3=O Chemical compound C[C@](CCC(N(*)*)=O)[C@@](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@](C3)O)[C@@]3C3)C1C2C3=O 0.000 description 2
- XHAZYUPJWKKNFT-UHFFFAOYSA-N CC(C)(CC1)CCC1[O](C)=C Chemical compound CC(C)(CC1)CCC1[O](C)=C XHAZYUPJWKKNFT-UHFFFAOYSA-N 0.000 description 1
- NCLUFDKDYSKWQI-CNHPDDOWSA-N CC[C@H]([C@@H](CCC[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(O)=O)[C@H]2O Chemical compound CC[C@H]([C@@H](CCC[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(O)=O)[C@H]2O NCLUFDKDYSKWQI-CNHPDDOWSA-N 0.000 description 1
- CJNVDKNEYRWTNW-LRMXTCDESA-N CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(O[C@H](CC1)C[C@@H]([C@H]3CC)[C@@]1(C)C(CC[C@@]1(C)C4CC[C@@H]1[C@H](C)CCC(O)=O)C4[C@@H]3O)=O)[C@H]2O Chemical compound CC[C@H]([C@H](C[C@@H](CC1)O)[C@@]1(C)C(CC1)C2C(CC3)[C@@]1(C)[C@H]3[C@H](C)CCC(O[C@H](CC1)C[C@@H]([C@H]3CC)[C@@]1(C)C(CC[C@@]1(C)C4CC[C@@H]1[C@H](C)CCC(O)=O)C4[C@@H]3O)=O)[C@H]2O CJNVDKNEYRWTNW-LRMXTCDESA-N 0.000 description 1
- QPPSYBFRUUBBKW-MMWFADNMSA-N C[C@H](CCC(O)=O)[C@@H](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@H](C3)O)C[C@H]3C3)C1C2C3=O Chemical compound C[C@H](CCC(O)=O)[C@@H](CC1)[C@@](C)(CCC2[C@@](C)(CC[C@H](C3)O)C[C@H]3C3)C1C2C3=O QPPSYBFRUUBBKW-MMWFADNMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Definitions
- the invention belongs to the field of medicine. Specifically, the present invention relates to a novel preparation and purification method of chenodeoxycholate.
- Farnesoid X Receptor is a member of the nuclear receptor (Nuclear Receptor) family. It is mainly expressed in the liver, small intestine and other intestinal systems, and is involved in bile acid metabolism and cholesterol metabolism. Bile acids have a variety of physiological functions and play an important role in the process of fat absorption, transport, distribution and cholesterol homeostasis.
- the farnesoid X receptor acts as a receptor for bile acids such as chenodeoxycholic acid and maintains the balance of bile acids in the body by regulating the expression of genes involved in bile acid metabolism.
- the farnesol X receptor also plays an important role in the dynamic balance of glucose and insulin resistance in the body.
- farnesol X receptor agonists are expected to be developed to treat non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, gallstones, primary biliary cirrhosis, liver cirrhosis, liver fibrosis, diabetes, and hypercholesterolemia , Atherosclerosis, obesity, hypertriglyceridemia and other drugs.
- the compound obeticholic acid is a selective farnesoid X receptor agonist, and its chemical name is 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholic-24-acid (3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholan-24-oic acid), which is useful for treating primary biliary cirrhosis (PBC), non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver related diseases.
- PBC primary biliary cirrhosis
- NASH non-alcoholic steatohepatitis
- obeticholic acid has been approved for marketing as an indication for primary biliary cirrhosis, and it is in phase III clinical research in the field of NASH.
- Patent WO02072598 discloses a method for synthesizing chenodeoxycholic acid derivatives with 3 ⁇ -dihydroxy-7-keto-5 ⁇ -cholin-24-acid as a starting material and undergoing 6-position alkylation and other steps.
- this patent There are many shortcomings in the synthetic method in, such as all intermediates and products need chromatographic column purification, the total yield of the reaction is very low (only 3.5%), the reaction step uses carcinogenic reagents, etc.
- the patent WO2006122977 discloses a method for synthesizing obeticholic acid by using 3 ⁇ -dihydroxy-7-keto-5 ⁇ -cholin-24-acid as the starting material through Aldol condensation and other steps.
- the intermediates are difficult to separate, the reaction steps are long, the yield of the configuration conversion step is low, and the impurities in the final product are difficult to remove.
- n 1 or 2
- M is NH 4 + , alkali metal ion, alkaline earth metal ion or transition metal ion;
- the method includes the following steps:
- the compound of formula (VI) is catalytically hydrogenated by the "one-pot method" and reduced with a metal hydride reducing agent
- R 1 and R 2 are selected from hydrogen, hydroxy, methyl, ethyl, methoxy, or R 1 and R 2 and the N atom to which they are connected together form a substituted or unsubstituted 5-7 membered heterocyclic ring, wherein, The heterocyclic ring includes 1-3 heteroatoms selected from the group consisting of N, O or S. In another preferred example, said R 1 and R 2 together form a structure selected from the group consisting of -CH 2 CH 2 CH 2 CH 2 -, -CH 2 CH 2 OCH 2 CH 2 -.
- the intermediate product is not separated and purified.
- step (a) includes: in anhydrous methanol, a compound of formula (VI) is used for catalytic hydrogenation, and then water and a metal hydride are added to react to obtain a compound of formula (V).
- the compound represented by formula (VI) is the following compound:
- the compound represented by formula (VI) is the following compound:
- the compound represented by formula (VI) is the following compound:
- the compound represented by formula (A) is selected from:
- the obtained compounds of formula I to IV have high purity, preferably with a purity of greater than 99.0%, further preferably with a purity of greater than 99.5%, and particularly preferably with a purity of greater than 99.7%.
- the obtained compound of formula I to IV contains dimer related substance formula (B) less than 0.1%, particularly preferably less than 0.05%.
- the obtained compound of formula I to IV contains isomer related substances of formula (C) less than 0.1%, more preferably less than 0.05%, and particularly preferably not detected.
- the inert solvent is selected from the following group: C1-C4 alcohol, water, or a combination thereof.
- the alcohol is selected from the group consisting of methanol, ethanol, isopropanol, tert-butanol, or a combination thereof.
- step (a) the catalytic hydrogenation is carried out in the presence of a palladium/carbon catalyst under hydrogen gas.
- step (a) includes: in anhydrous methanol, a compound of formula (VI) is used for catalytic hydrogenation, and then water and a metal hydride are added to react to obtain a compound of formula (V).
- reaction temperature in step (a) is 5 to 150°C, preferably in the range of 30 to 120°C, particularly preferably 50 to 100°C.
- the pressure of catalytic hydrogenation in step (a) is 1-20 atm, preferably in the range of 2-10 atm.
- the metal hydride reducing agent includes borohydride, lithium tri-tert-butoxyaluminum hydride, among which, borohydride is preferred, and more preferably is sodium borohydride and boron. Potassium hydride is particularly preferably sodium borohydride.
- step (a) the molar ratio of the metal hydride to the compound of formula (VI) is 5:1 to 1:1, more preferably 3:1 to 1:1, particularly preferably 2:1.
- step (a) the reduction of the metal hydride is carried out under alkaline conditions.
- the alkaline condition is in the presence of sodium hydroxide or potassium hydroxide.
- the molar ratio of the sodium hydroxide or potassium hydroxide to the compound of formula (VI) is 50:1 to 1:5, more preferably 30:1 to 10:1.
- the method further comprises: preparing the compound of formula (VI) by the following method:
- the compound Or its hydrochloride is selected from the following group: ammonium chloride, hydroxylamine hydrochloride, methylamine hydrochloride, N,O-dimethylhydroxylamine hydrochloride, or a combination thereof; preferably ammonium chloride.
- step a) the compound The molar ratio of the added amount to the compound of formula (VII) is 10:1 to 1:1, more preferably 5:1 to 1:1, particularly preferably 2:1 to 1:1.
- the condensing agent in step a) is selected from the group consisting of N,N'-carbonyldiimidazole (CDI), EDC1, DIC, DCC, HATU, HBTU, TBTU and PyBOP; preferably HATU , HBTU and PyBOP; PyBOP is particularly preferred.
- CDI N,N'-carbonyldiimidazole
- EDC1 EDC1
- DIC DIC
- DCC HATU
- HBTU HBTU
- TBTU and PyBOP preferably HATU , HBTU and PyBOP
- PyBOP is particularly preferred.
- the molar ratio of the added amount of the condensing agent to the compound of formula (VII) is 10:1 to 1:5, more preferably 5:1 to 1:1, particularly preferably It is 2:1.
- the step a) also includes the step of adding an activator, and the activator is selected from the group consisting of DMAP, HOBt, 4-PPY, DIPEA and Et 3 N; preferably DIPEA.
- the step a) is carried out in an aprotic solvent; preferably, the aprotic solvent is selected from the group consisting of dichloromethane, acetonitrile, N,N-dimethyl Formamide, dimethyl sulfoxide, or a combination thereof; preferably N,N-dimethylformamide.
- the aprotic solvent is selected from the group consisting of dichloromethane, acetonitrile, N,N-dimethyl Formamide, dimethyl sulfoxide, or a combination thereof; preferably N,N-dimethylformamide.
- the step b) is carried out in a solvent, and the solvent is selected from the group consisting of dichloromethane, acetonitrile, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, Or a combination thereof; dichloromethane is preferred.
- the Lewis acid in step b) is selected from the group consisting of hydrochloric acid, acetic acid, p-toluenesulfonic acid, boron trifluoride ether solution, boron trifluoride acetonitrile solution, or a combination thereof; preferably It is a solution of boron trifluoride in ether.
- step b) the molar ratio of the added Lewis acid to the compound of formula (VIII) is 10:1 to 1:3, more preferably 4:1 to 2:1.
- the method further includes the step of preparing the compound of formula (VIII) by the following method:
- the condensing agent is selected from the group consisting of N,N'-carbonyldiimidazole (CDI), EDCl, DIC, DCC, HATU, HBTU, TBTU, PyBOP , Or a combination thereof; preferably HATU, HBTU, PyBOP, or a combination thereof; more preferably PyBOP.
- CDI N,N'-carbonyldiimidazole
- EDCl EDCl
- DIC DIC
- DCC HATU, HBTU, TBTU, PyBOP , Or a combination thereof; preferably HATU, HBTU, PyBOP, or a combination thereof; more preferably PyBOP.
- step c) the compound The molar ratio of the added amount to the compound of formula (IX) is 10:1 to 1:1, more preferably 5:1 to 1:1, and particularly preferably 2:1 to 1:1.
- the molar ratio of the added amount of the condensing agent to the compound of formula (IX) is 10:1 to 1:5, more preferably 5:1 to 1:1, particularly preferably It is 2:1.
- the step c) also includes the step of adding an activator, the activator is selected from the group consisting of DMAP, HOBt, 4-PPY, DIPEA and Et 3 N; preferably DIPEA.
- the step c) is carried out in an aprotic solvent; preferably, the aprotic solvent is selected from the group consisting of dichloromethane, acetonitrile, N,N-dimethyl Formamide, dimethyl sulfoxide, or a combination thereof; preferably N,N-dimethylformamide.
- the aprotic solvent is selected from the group consisting of dichloromethane, acetonitrile, N,N-dimethyl Formamide, dimethyl sulfoxide, or a combination thereof; preferably N,N-dimethylformamide.
- the base in step d) is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide ( LDA), or a combination thereof; preferably lithium diisopropylamide.
- the molar ratio of the added amount of trimethylchlorosilane to the compound of formula (X) is 20:1 to 1:1, more preferably 15:1 to 1:1 , Especially preferably 10:1.
- the molar ratio of the added amount of the base to the compound of formula (X) is 20:1 to 1:1, more preferably 15:1 to 1:1, particularly preferably 10:1.
- the step d) is carried out in a solvent selected from the group consisting of: dichloromethane, tetrahydrofuran, diethyl ether, toluene, 1,4-dioxane, acetonitrile, N,N-dimethyl Methyl formamide, dimethyl sulfoxide, or a mixed solvent thereof, more preferably tetrahydrofuran.
- a solvent selected from the group consisting of: dichloromethane, tetrahydrofuran, diethyl ether, toluene, 1,4-dioxane, acetonitrile, N,N-dimethyl Methyl formamide, dimethyl sulfoxide, or a mixed solvent thereof, more preferably tetrahydrofuran.
- the salt-forming crystals include:
- step (b1) Mix the 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholin-24-acid obtained in step (a) with pure water, add an aqueous sodium hydroxide solution, and stir until it is substantially dissolved to obtain a clear solution;
- the weight ratio of the 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholin-24-acid to pure water is 40:1 to 1:5, more preferably 10:1 ⁇ 1:3, particularly preferably 5:1.
- the weight ratio of the 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholin-24-acid to the aqueous sodium hydroxide solution is 10:1 to 1:10, more preferably 3 : 1 to 1:5, particularly preferably 1:0.97 to 1:3.
- the concentration of the sodium hydroxide aqueous solution is 0.5-5 mol.L -1 , more preferably 2-3 mol.L -1 , particularly preferably 2.52 mol.L -1 .
- the concentration of the aqueous solution containing metal ions Mg 2+ is 0.1-10, more preferably 0.3-5, particularly preferably 0.5-2 mol ⁇ L -1 .
- the concentration of the aqueous solution containing metal ions Ca 2+ is 0.1-20, more preferably 0.5-10, and particularly preferably 2-5 mol ⁇ L -1 .
- the salt-forming crystals include:
- step (b4) Dissolve the 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholin-24-acid obtained in step (a) in methanol, slowly drip into the methanol solution of sodium hydroxide, and stir until it is almost dissolved to obtain Clear solution
- the inventors After long-term and in-depth research, the inventors have obtained a method for preparing 3 ⁇ ,7 ⁇ -dihydroxy-6 ⁇ -ethyl-5 ⁇ -cholin-24-acid or its salt.
- the method has the characteristics of short synthetic route, easy purification of intermediates and mild reaction conditions, and the obtained corresponding cholic acid or bile acid salt has higher purity and better product quality, and is suitable for pharmaceutical production. Based on the above findings, the inventor completed the present invention.
- the compound of the formula (A) structure of the present invention can be prepared by the following general routes one and two:
- the reaction is carried out in the presence of a condensing agent and/or an activator in an aprotic solvent at a temperature of -20 to 60°C.
- the condensing agent is selected from N,N'-carbonyldiimidazole (CDI), EDCl, DIC, DCC, HATU, HBTU, TBTU and PyBOP, more preferably PyBOP.
- the activating agent is selected from DMAP, HOBt, 4-PPY, DIPEA and Et 3 N, more preferably DIPEA;
- the aprotic solvent is dichloromethane, acetonitrile, N,N-dimethylformamide, Dimethyl sulfoxide or its mixed solvent is more preferably N,N-dimethylformamide;
- the reaction temperature is preferably -5 to 50°C, more preferably 0 to 30°C.
- the reaction in this step is carried out in a protic solvent, an alkaline aqueous solution and a temperature of 5 to 150°C.
- the hydrogenation reaction is under 1-20 atmospheres of hydrogen, using palladium/carbon as a catalyst;
- the metal hydride reducing agent can be sodium borohydride or potassium borohydride, more preferably sodium borohydride;
- the protic solvent is selected from methanol, ethanol, isopropanol, tert-butanol, water or a mixed solvent thereof, preferably a mixed solvent of methanol and water;
- the alkaline aqueous solution is selected from sodium hydroxide aqueous solution and potassium hydroxide aqueous solution.
- the reaction temperature is 5 to 150°C, more preferably 50 to 100°C.
- the compound of formula (A) is prepared by the following method:
- a condensing agent In the presence of a condensing agent and/or an activator, it is carried out at a neutralization temperature of an aprotic solvent from -20 to 60°C.
- the condensing agent is N,N'-carbonyl diimidazole (CDI), EDC1, DIC, DCC, HATU, HBTU, TBTU and PyBOP, more preferably PyBOP;
- the activating agent is DMAP, HOBt, 4- PPY, DIPEA and Et 3 N, more preferably DIPEA;
- the aprotic solvent is dichloromethane, acetonitrile, N,N-dimethylformamide, dimethyl sulfoxide, or a mixed solvent thereof, more preferably It is N,N-dimethylformamide.
- the reaction temperature is preferably -5 to 40°C, more preferably 0 to 30°C.
- This reaction can be carried out in an aprotic solvent.
- the base is selected from sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium hydride or lithium diisopropylamide (LDA), more preferably Is lithium diisopropylamide (LDA);
- the aprotic solvent is selected from dichloromethane, tetrahydrofuran, ether, toluene, 1,4-dioxane, acetonitrile, N,N-dimethylformamide , Dimethyl sulfoxide or its mixed solvent, more preferably tetrahydrofuran.
- the reaction temperature is preferably -100 to 40°C, more preferably -70 to 30°C.
- the compound of formula (VIII) can be directly used in the next reaction without further purification.
- the Lewis acid is preferably boron trifluoride etherate;
- the solvent is selected from methylene chloride, acetonitrile, dimethyl sulfoxide, tetrahydrofuran, 1,4-dioxane, or Mixed solvent; more preferably dichloromethane.
- the reaction temperature is preferably -100 to 70°C, more preferably -70 to 40°C.
- the reaction in this step is carried out in a protic solvent, an alkaline aqueous solution and a temperature of 0 to 150°C.
- the hydrogenation reaction uses palladium/carbon as a catalyst under 1-20 atmospheres of hydrogen; the borohydride is sodium borohydride or potassium borohydride, more preferably sodium borohydride.
- the protic solvent is selected from the following group: methanol, ethanol, isopropanol, tert-butanol, water, or a mixed solvent thereof, preferably a mixed solvent of methanol and water.
- the alkaline aqueous solution is selected from sodium hydroxide aqueous solution and potassium hydroxide aqueous solution.
- the reaction temperature is 5 to 150°C, more preferably 50 to 100°C.
- the preparation method of the present invention has a series of advantages. Its main advantages include:
- the present invention adopts the "one-pot method" process, which has stronger production continuity and is more suitable for large-scale production.
- the corresponding cholate obtained by the present invention has higher purity and better product quality, especially the magnesium, calcium, sodium and potassium salts of obeticholic acid prepared by the method of the present application Less impurities, suitable for pharmaceutical production.
- reaction mixture was slowly poured into 5% sodium bicarbonate aqueous solution (5L), solids separated out, stirred evenly for 2h, filtered, washed with pure water (500ml ⁇ 8), and dried in vacuum to obtain a crude product.
- the crude product was transferred to a flask, added with tetrahydrofuran (400ml), refluxed and beaten, cooled down, filtered, washed with tetrahydrofuran (50ml ⁇ 3) and the filter cake was dried under vacuum to obtain the target compound (83.5g, 86%).
- Infrared spectra (IR) absorption characteristic 3401 ⁇ 5cm -1, 2935 ⁇ 5cm -1, 2871 ⁇ 5cm -1, 1555 ⁇ 5cm -1, 1449 ⁇ 5cm -1, 1414 ⁇ 5cm -1, 1377 ⁇ 5cm - 1. 1159 ⁇ 5cm -1 , 1064 ⁇ 5cm -1 and 603 ⁇ 5cm -1 .
- Infrared spectra (IR) absorption characteristic 3423 ⁇ 5cm -1, 2958 ⁇ 5cm -1, 2935 ⁇ 5cm -1, 2871 ⁇ 5cm -1, 2122 ⁇ 5cm -1, 1640 ⁇ 5cm -1, 1559 ⁇ 5cm - 1. 1451 ⁇ 5cm -1 , 1406 ⁇ 5cm -1 , 1378 ⁇ 5cm -1 , 1160 ⁇ 5cm -1 , 1065 ⁇ 5cm -1 and 603 ⁇ 5cm -1 .
- Infrared spectra (IR) absorption characteristic 3409 ⁇ 5cm -1, 2935 ⁇ 5cm -1, 2871 ⁇ 5cm -1, 1643 ⁇ 5cm -1, 1555 ⁇ 5cm -1, 1465 ⁇ 5cm -1, 1451 ⁇ 5cm - 1.
- Infrared spectra (IR) absorption characteristic 3407 ⁇ 5cm -1, 2935 ⁇ 5cm -1, 2871 ⁇ 5cm - 1,1553 ⁇ 5cm -1, 1447 ⁇ 5cm -1, 1417 ⁇ 5cm -1, 1377 ⁇ 5cm - 1. 1159 ⁇ 5cm -1 , 1064 ⁇ 5cm -1 and 603 ⁇ 5cm -1 .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (10)
- 如权利要求1中所述的方法,其特征在于,所述的步骤(a)中,所述的惰性溶剂选自下组:C1-C4的醇、水,或其组合。
- 如权利要求1中所述的方法,其特征在于,所述的步骤(a)中,所述的醇选自下组:甲醇、乙醇、异丙醇、叔丁醇,或其组合。
- 如权利要求1中所述的方法,其特征在于,所述的步骤(a)中,所述的惰性溶剂选自下组:无水甲醇,或甲醇:水(v/v)=1:100~100:1的混合溶剂,优选为甲醇:水(v/v)=0.5:1~5:1。
- 如权利要求6中所述的方法,其特征在于,所述的步骤a)中的缩合剂选自下组:N,N'-羰基二咪唑(CDI)、EDCl、DIC、DCC、HATU、HBTU、TBTU和PyBOP;优选HATU、HBTU和PyBOP;特别优选PyBOP。
- 如权利要求1所述的方法,其特征在于,所述的成盐结晶包括:(b1)将步骤(a)得到的3α,7α-二羟基-6α-乙基-5β-胆-24-酸和纯水混合,加入氢氧化钠水溶液,搅拌至基本溶清,得到澄清溶液;(b2)向所述的澄清溶液中缓缓滴加含Mg 2+或Ca 2+的水溶液,继续搅拌直至产生沉淀;(b3)对所述的沉淀进行过滤,洗涤,真空干燥,得到式(A)化合物。
- 如权利要求1所述的方法,其特征在于,所述的成盐结晶包括:(b4)将步骤(a)得到的3α,7α-二羟基-6α-乙基-5β-胆-24-酸溶于甲醇中,缓慢滴入氢氧化钠甲醇溶液,搅拌至基本溶清,得到澄清溶液;(b5)对所述的澄清溶液进行浓缩至干,然后加入丙酮浓缩带干,得到固体残留物;(b6)向所述的残留物中加入丙酮打浆,过滤并真空干燥,得到式(A)化合物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020217033693A KR20210141616A (ko) | 2019-03-19 | 2020-03-19 | 케노데옥시콜산 유도체의 제조 방법 |
JP2021559466A JP7344983B2 (ja) | 2019-03-19 | 2020-03-19 | ケノデオキシコール酸誘導体の調製方法 |
US17/440,947 US20220162256A1 (en) | 2019-03-19 | 2020-03-19 | Method for preparing chenodeoxycholic acid derivative |
EP20773082.1A EP3943502A4 (en) | 2019-03-19 | 2020-03-19 | METHOD FOR PREPARING A CHENODESOXYCHOLIC ACID DERIVATIVE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910210103.3A CN111718388A (zh) | 2019-03-19 | 2019-03-19 | 鹅去氧胆酸衍生物的制备方法 |
CN201910210103.3 | 2019-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020187298A1 true WO2020187298A1 (zh) | 2020-09-24 |
Family
ID=72519634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/080244 WO2020187298A1 (zh) | 2019-03-19 | 2020-03-19 | 鹅去氧胆酸衍生物的制备方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220162256A1 (zh) |
EP (1) | EP3943502A4 (zh) |
JP (1) | JP7344983B2 (zh) |
KR (1) | KR20210141616A (zh) |
CN (1) | CN111718388A (zh) |
WO (1) | WO2020187298A1 (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072598A1 (en) | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
WO2006122977A2 (en) | 2005-05-19 | 2006-11-23 | Erregierre S.P.A. | PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID |
CN105669811A (zh) * | 2014-11-17 | 2016-06-15 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
CN106632564A (zh) * | 2015-10-30 | 2017-05-10 | 苏州泽璟生物制药有限公司 | 奥贝胆酸盐及其无定形物和药物组合物 |
US20180099991A1 (en) * | 2016-10-07 | 2018-04-12 | Lupin Limited | Salts of obeticholic acid |
CN108456238A (zh) * | 2017-02-20 | 2018-08-28 | 浙江京新药业股份有限公司 | 奥贝胆酸衍生物及奥贝胆酸的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106279328A (zh) * | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
CN106749466B (zh) * | 2015-11-23 | 2019-05-21 | 南京济群医药科技股份有限公司 | 一种高纯度奥贝胆酸的制备方法 |
CN106046095B (zh) * | 2016-06-06 | 2017-02-22 | 南京理工大学 | 奥贝胆酸的合成方法 |
CN108676049A (zh) * | 2017-11-02 | 2018-10-19 | 华东师范大学 | 一种奥贝胆酸,熊去氧胆酸及7-酮基石胆酸的制备方法 |
WO2019170521A1 (en) * | 2018-03-07 | 2019-09-12 | Moehs Iberica, S.L. | Synthesis of obeticholic acid and synthesis intermediate |
WO2020039449A1 (en) * | 2018-08-24 | 2020-02-27 | Solara Active Pharma Sciences Limited | An improved process for the preparation of obeticholic acid and intermediates used in the process thereof |
-
2019
- 2019-03-19 CN CN201910210103.3A patent/CN111718388A/zh active Pending
-
2020
- 2020-03-19 EP EP20773082.1A patent/EP3943502A4/en active Pending
- 2020-03-19 JP JP2021559466A patent/JP7344983B2/ja active Active
- 2020-03-19 US US17/440,947 patent/US20220162256A1/en active Pending
- 2020-03-19 WO PCT/CN2020/080244 patent/WO2020187298A1/zh unknown
- 2020-03-19 KR KR1020217033693A patent/KR20210141616A/ko not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072598A1 (en) | 2001-03-12 | 2002-09-19 | Roberto Pellicciari | Steroids as agonists for fxr |
WO2006122977A2 (en) | 2005-05-19 | 2006-11-23 | Erregierre S.P.A. | PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID |
CN105669811A (zh) * | 2014-11-17 | 2016-06-15 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
CN106632564A (zh) * | 2015-10-30 | 2017-05-10 | 苏州泽璟生物制药有限公司 | 奥贝胆酸盐及其无定形物和药物组合物 |
US20180099991A1 (en) * | 2016-10-07 | 2018-04-12 | Lupin Limited | Salts of obeticholic acid |
CN108456238A (zh) * | 2017-02-20 | 2018-08-28 | 浙江京新药业股份有限公司 | 奥贝胆酸衍生物及奥贝胆酸的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2022527990A (ja) | 2022-06-07 |
EP3943502A1 (en) | 2022-01-26 |
EP3943502A4 (en) | 2022-11-23 |
CN111718388A (zh) | 2020-09-29 |
JP7344983B2 (ja) | 2023-09-14 |
US20220162256A1 (en) | 2022-05-26 |
KR20210141616A (ko) | 2021-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2102224B2 (en) | CRYSTALLINE FORM OF 1- (ß-D-GLUCOPYRANOSYL) -4 -METHYL- 3- [5- (4 -FLUOROPHENYL) -2-THIENYLMETHYL]BENZENE HEMIHYDRATE | |
CN101787069A (zh) | 薯蓣皂苷元哌嗪类衍生物及其制备方法 | |
CN115884978A (zh) | 制备胆酸衍生物的方法及其原料 | |
WO2009094847A1 (fr) | Dérivé hydroxyle de capécitabine, procédés de préparation et d' utilisation de la capécitabine | |
WO2020187298A1 (zh) | 鹅去氧胆酸衍生物的制备方法 | |
CN105753733A (zh) | Ahu377的晶型及其制备方法与用途 | |
AU2020406455B2 (en) | Efficient process for making 6-carboxy benzoxazole derivatives | |
CN110563795B (zh) | 含有1,3,4噁二唑或1,3,4噻二唑片段的薯蓣皂苷元衍生物的制备方法及应用 | |
CN109641934A (zh) | 胆酸衍生物游离碱,晶型及其制备方法和应用 | |
CN102659638A (zh) | 一种益母草碱的合成方法 | |
JP7308811B2 (ja) | ステロイド系誘導体fxrアゴニストの製造方法 | |
CN111285914B (zh) | 一种奥贝胆酸的制备方法 | |
CN109134577B (zh) | 一种3α-羟基-5α-胆烷酸的合成方法 | |
CN111454315A (zh) | 一种雄甾-16-烯-3β-醇的合成方法 | |
CN113072514A (zh) | 轮环藤宁及其中间体的制备方法 | |
WO1995016699A1 (fr) | Derive de steroide | |
JPH0495049A (ja) | ビフェニル‐5,5’‐ビス‐アルカン酸誘導体、その製造法およびその用途 | |
JPS6054960B2 (ja) | 抗しゆよう性セプタシジン類似体 | |
WO2023131017A1 (zh) | 一种稠环衍生物的晶型、其制备方法及其应用 | |
CN114133421B (zh) | 一种β-鼠胆酸的制备方法 | |
WO2024087782A1 (zh) | 一种gpr139受体激动剂、其制备方法及其应用 | |
CN106397312B (zh) | 一种制备glyt-1抑制剂的方法 | |
CN112409432A (zh) | 一种依西美坦的合成方法 | |
CN116284018A (zh) | 一种呋喃并[2,3-b]喹啉衍生物的制备方法及其应用 | |
WO2013055244A1 (en) | Preparation of protoescigenin from escin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20773082 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021559466 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217033693 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020773082 Country of ref document: EP Effective date: 20211019 |